Protective shield of hydroxychloroquine molecules guarding blood vessels from infection in vasculitis.

Can Hydroxychloroquine Prevent Infections in Vasculitis Patients?

Elliot Brynn monogram
Elliot Brynn in Health & Wellness October 2026 • 4 min read.

"Emerging research suggests the antimalarial drug hydroxychloroquine may offer a protective effect against infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV)."


Infections are a significant concern for patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), a group of autoimmune diseases characterized by inflammation of small blood vessels. AAV often requires treatment with immunosuppressive drugs like rituximab, which, while effective in controlling the disease, can increase the risk of opportunistic infections. This is because these medications suppress the immune system, making patients more vulnerable to various pathogens.

A recent study by Kronbichler et al., published in the journal Annals of the Rheumatic Diseases, shed light on the frequency and impact of severe infections in AAV patients treated with rituximab. The study revealed that a notable proportion of patients experienced severe or life-threatening infections within two years of starting rituximab. Respiratory tract infections were particularly common, and opportunistic pathogens were frequently identified in patients with positive cultures.

Traditionally, trimethoprim/sulfamethoxazole has been used as a prophylactic measure to prevent Pneumocystis jirovecii pneumonia, a serious lung infection, in patients with AAV. However, concerns about adverse events associated with this medication have prompted researchers to explore alternative strategies. Hydroxychloroquine, an antimalarial drug with known immunomodulatory properties, has emerged as a potential candidate for infection prevention in this patient population.

AI Search Multiple angles on this topic

Uses and Safety

Hydroxychloroquine, sold under the brand name Plaquenil, is an oral medication used to prevent and treat malaria where malaria remains sensitive to chloroquine. It is also used for rheumatoid arthritis and lupus, including systemic lupus erythematosus. The Mayo Clinic reports that some people may experience agitation, irritability, abnormal behavior, depression, or suicidal thoughts within the first month of treatment, requiring prompt medical attention.

Established Clinical Uses

The Cleveland Clinic describes hydroxychloroquine as a medication used to treat autoimmune conditions such as rheumatoid arthritis and lupus. It can also prevent and treat malaria. These established uses do not by themselves establish hydroxychloroquine as a general preventive treatment for infections in vasculitis patients. Its role should therefore be distinguished from the treatment of the underlying autoimmune disease or malaria prevention.

Historical Context

Hydroxychloroquine has an established history as a medication for malaria and autoimmune conditions. Its use in lupus and rheumatoid arthritis provides the main clinical context for considering it in immune-mediated diseases. However, the available material here does not document specific milestones or foundational discoveries connecting it to infection prevention in vasculitis patients.

Hydroxychloroquine: A Promising Alternative for Infection Prevention?

Protective shield of hydroxychloroquine molecules guarding blood vessels from infection in vasculitis.

Hydroxychloroquine has been used for decades to treat malaria, lupus, and rheumatoid arthritis. It works by modulating the immune system, reducing inflammation and preventing the overactivation of immune cells. Accumulating evidence suggests that hydroxychloroquine may also have a protective effect against infections.

Several studies have demonstrated the potential benefits of hydroxychloroquine in preventing infections. For instance, a nationwide cohort study of patients with systemic lupus erythematosus (SLE) found that hydroxychloroquine users had a reduced risk of infection compared to non-users. Similarly, a Spanish cohort study observed a negative association between the duration of antimalarial use and severe infections in SLE patients.

  • Reduced Infection Risk: Studies in SLE patients show hydroxychloroquine use is linked to lower infection rates.
  • Broad-Spectrum Activity: In vitro research indicates hydroxychloroquine is effective against various bacteria, fungi, and viruses.
  • Potential for Pneumocystis Prevention: Research suggests chloroquine, similar to hydroxychloroquine, may inhibit Pneumocystis jirovecii.
AI Search Multiple angles on this topic

Evidence Status

The available source material does not provide a study or review evaluating whether hydroxychloroquine prevents infections specifically in vasculitis patients. It describes the drug's established uses in malaria, rheumatoid arthritis, and lupus. Any conclusion about infection prevention in vasculitis would therefore require evidence beyond the sources provided here.

Limits of the Evidence

The listed material does not report clinical failures, negative trials, or measured infection outcomes for hydroxychloroquine in vasculitis patients. It does, however, identify potential behavioral and mood-related adverse effects, including agitation, depression, and suicidal thoughts. These reported safety concerns reinforce the need for individualized medical supervision rather than assuming preventive benefit.

What Can Be Compared

The provided sources establish hydroxychloroquine's roles in malaria prevention and treatment and in autoimmune conditions such as rheumatoid arthritis and lupus. They do not compare it with other infection-prevention strategies for vasculitis patients. A treatment comparison would therefore be premature based on this source set alone.

The mechanisms by which hydroxychloroquine protects against infections are not fully understood. However, it is believed that the drug can interfere with the entry of pathogens into cells, inhibit their replication, and modulate the immune response to infection. In vitro studies have shown that chloroquine and hydroxychloroquine have broad-spectrum activity against different bacteria, fungi, and viruses at clinically achievable plasma concentrations.

Future Directions and Clinical Implications

The observations from Kronbichler et al. and other studies suggest that hydroxychloroquine may be a valuable addition to the armamentarium of infection prevention strategies in AAV patients, particularly those treated with rituximab. The authors of the original article speculate that hydroxychloroquine may also decrease the risk of infectious complications and may confer additional benefits to patients with AAV.

AI Search Multiple angles on this topic

Overall Interpretation

Hydroxychloroquine is an established medication for malaria and certain autoimmune diseases, including lupus and rheumatoid arthritis. The supplied sources do not establish that it prevents infections in people with vasculitis. Decisions about its use should account for its intended indication, potential adverse effects, and the patient's clinical circumstances.

Research Needs

The available material leaves an important evidence gap regarding hydroxychloroquine and infection prevention in vasculitis. Future work would need to evaluate this question directly in vasculitis populations. Such research should also consider the drug's established uses and reported safety concerns.

Clinical Context

Hydroxychloroquine is used across more than one clinical context, including malaria and autoimmune diseases such as lupus and rheumatoid arthritis. That broad use can make it difficult to infer a preventive effect for a different population or purpose. The provided sources do not address healthcare-system factors, access barriers, or broader challenges specific to infection prevention in vasculitis.

Patient Considerations

Patients may encounter hydroxychloroquine under the brand name Plaquenil or as an oral hydroxychloroquine sulfate medication. Its potential benefits depend on the condition being treated, while reported effects such as agitation, depression, or suicidal thoughts may require urgent discussion with a clinician. The available sources do not provide patient-reported outcomes or real-world infection data for people with vasculitis.

What the AAV infection figures represent

  • 7.5 serious infections per 100 patient-yearsIn a separate cohort, serious infections occurred at a rate of 7.5 per 100 patient-years over 891.2 patient-years of follow-up.[1]
  • 14.61% versus 5.93% cumulative incidenceDuring maintenance treatment, cumulative serious-infection incidence was 14.61% with rituximab and 5.93% with azathioprine; the reported confidence intervals were 10.19–19.61% and 1.19–13.26%, respectively.[2]

How the AAV and related evidence compares

A retrospective analysis examined infection episodes among Chinese patients with AAV at a single centre. That setting describes the source population and design; the excerpt does not establish how well its findings apply to other settings.[3]

The cited AAV recommendations encourage Pneumocystis jirovecii prophylaxis for patients receiving cyclophosphamide, while giving no concrete recommendation for rituximab. This provides a treatment-context comparison, not evidence that hydroxychloroquine prevents infection.[4]

The HAVEN trial design indicates that a comparison of hydroxychloroquine with placebo would require at least 200 patients to test its primary outcome with sufficient power. If the result only modestly favored hydroxychloroquine, an extended study might still be needed to estimate efficacy accurately.[5]

What remains unresolved for hydroxychloroquine in AAV

  • Would hydroxychloroquine change infection outcomes in AAV, rather than the renal-damage outcome reported in the cohort comparison?[6]
  • Would a hydroxychloroquine-placebo comparison show a sufficiently large difference to estimate efficacy without an extended study?[5]
  • What will the ongoing HAVEN study show about survival among patients with AAV?[6]

Sources

  1. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients (pmc.ncbi.nlm.nih.gov)
  2. Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis (pmc.ncbi.nlm.nih.gov)
  3. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study (pmc.ncbi.nlm.nih.gov)
  4. Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis (pmc.ncbi.nlm.nih.gov)
  5. The HAVEN study—hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan (pmc.ncbi.nlm.nih.gov)
  6. Hydroxychloroquine as an add-on therapy for the induction therapy of MPO-AAV: a retrospective observational cohort study (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the significance of infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) and how is it related to rituximab treatment?

Infections are a major concern for individuals with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) because AAV itself is a condition marked by blood vessel inflammation. The treatments, like rituximab, used to manage AAV often suppress the immune system. While rituximab is effective in controlling the disease, it increases the risk of opportunistic infections. This makes patients more susceptible to various pathogens. A recent study highlighted that a notable proportion of patients experienced severe or life-threatening infections within two years of starting rituximab.

2

How does hydroxychloroquine work, and what are its potential benefits for patients with AAV?

Hydroxychloroquine is an antimalarial drug that has been used for decades to treat malaria, lupus, and rheumatoid arthritis. It functions by modulating the immune system, which reduces inflammation and prevents the overactivation of immune cells. In the context of AAV, the drug may have a protective effect against infections. Several studies show that hydroxychloroquine can reduce the risk of infection. The mechanisms behind hydroxychloroquine's protective effects include interfering with pathogen entry into cells, inhibiting pathogen replication, and modulating the immune response to infection.

3

What are the known strategies for preventing infections in patients with AAV, and why is hydroxychloroquine being considered as an alternative?

Traditionally, trimethoprim/sulfamethoxazole has been used to prevent Pneumocystis jirovecii pneumonia in AAV patients. However, concerns about adverse events associated with this medication have led researchers to explore alternatives. Hydroxychloroquine has emerged as a promising candidate due to its known immunomodulatory properties and potential to prevent infections. Furthermore, in vitro research indicates hydroxychloroquine's broad-spectrum activity against various pathogens.

4

Can you explain the connection between hydroxychloroquine and infection prevention based on current research?

Research indicates that hydroxychloroquine use is linked to lower infection rates in patients. For instance, a study in systemic lupus erythematosus (SLE) patients found that hydroxychloroquine users had a reduced risk of infection compared to non-users. In vitro studies show that hydroxychloroquine has broad-spectrum activity against different bacteria, fungi, and viruses. Also, research suggests that hydroxychloroquine may also prevent Pneumocystis jirovecii, similar to chloroquine.

5

What are the clinical implications of using hydroxychloroquine for AAV patients, and what future directions might be explored?

The current research suggests hydroxychloroquine may be a valuable addition to infection prevention strategies in AAV patients, especially those on rituximab. Hydroxychloroquine may decrease the risk of infectious complications and may confer additional benefits to patients with AAV. The observations from Kronbichler et al. and other studies highlight the potential benefits of hydroxychloroquine. Future research may focus on further elucidating the mechanisms of action and optimizing the use of hydroxychloroquine in this patient population.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.